Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 476.46 thousand shares for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-04.
Discontinued › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2016-08-04
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-06-30 was 79.50K shares, a 396.88% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-03-31 was 396.96K shares, a 46.08% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-12-31 was 6.50K shares.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-09-30 was 0.00 shares.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 294.25K shares, a 28.45% increase from fiscal 2014.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 229.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2016-06-30 | 79.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 476.46K shares 10-Q · filed 2016-08-04 | 482.96K shares derived: sum of 3 quarters · filed 2016-08-04 | 482.96K shares derived: sum of 4 quarters · filed 2016-08-04 |
| 2016-03-31 | 396.96K shares 10-Q · filed 2016-05-10 | 403.46K shares derived: sum of 2 quarters · filed 2016-05-10 | 403.46K shares derived: sum of 3 quarters · filed 2016-05-10 | 419.46K shares derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-12-31 | 6.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 6.50K shares derived: sum of 2 quarters · filed 2016-03-14 | 22.50K shares derived: sum of 3 quarters · filed 2016-03-14 | 294.25K shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 0.00 shares 10-Q · filed 2015-11-10 | 16.00K shares derived: sum of 2 quarters · filed 2015-11-10 | 287.75K shares 10-Q · filed 2015-11-10 | |
| 2015-06-30 | 16.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | 287.75K shares 10-Q · filed 2015-08-06 | ||
| 2015-03-31 | 271.75K shares 10-Q · filed 2015-05-12 | |||
| 2014-12-31 | 229.08K shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |